Hebei Changshan Biochem Pharma
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. The company offers crude heparin sodium, heparin sodium API, heparin sodium injections, low molecular weight heparin calcium i… Read more
Hebei Changshan Biochem Pharma (300255) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.021x
Based on the latest financial reports, Hebei Changshan Biochem Pharma (300255) has a cash flow conversion efficiency ratio of -0.021x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-30.86 Million) by net assets (CN¥1.48 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hebei Changshan Biochem Pharma - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Hebei Changshan Biochem Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hebei Changshan Biochem Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hebei Changshan Biochem Pharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mapfre S.A
PINK:MPFRF
|
0.000x |
|
Nova Ljubljanska Banka d.d.
F:N1V1
|
0.040x |
|
Huber+suhner AG
SW:HUBN
|
0.100x |
|
Axfood AB
ST:AXFO
|
0.286x |
|
Enova International Inc
NYSE:ENVA
|
0.373x |
|
SEEK Limited
F:SLD
|
0.035x |
|
Bill Com Holdings Inc
NYSE:BILL
|
0.028x |
|
Plaza S.A
SN:MALLPLAZA
|
0.013x |
Annual Cash Flow Conversion Efficiency for Hebei Changshan Biochem Pharma (2008–2024)
The table below shows the annual cash flow conversion efficiency of Hebei Changshan Biochem Pharma from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.54 Billion | CN¥56.22 Million | 0.037x | +95.34% |
| 2023-12-31 | CN¥1.80 Billion | CN¥33.73 Million | 0.019x | +1731.13% |
| 2022-12-31 | CN¥3.05 Billion | CN¥3.13 Million | 0.001x | +9.49% |
| 2021-12-31 | CN¥3.07 Billion | CN¥2.87 Million | 0.001x | +101.45% |
| 2020-12-31 | CN¥2.85 Billion | CN¥-183.58 Million | -0.064x | -201.33% |
| 2019-12-31 | CN¥2.72 Billion | CN¥-58.13 Million | -0.021x | -118.40% |
| 2018-12-31 | CN¥2.52 Billion | CN¥292.81 Million | 0.116x | +74.17% |
| 2017-12-31 | CN¥2.44 Billion | CN¥162.28 Million | 0.067x | -11.29% |
| 2016-12-31 | CN¥2.29 Billion | CN¥171.96 Million | 0.075x | +409.43% |
| 2015-12-31 | CN¥1.57 Billion | CN¥-38.14 Million | -0.024x | +59.24% |
| 2014-12-31 | CN¥1.43 Billion | CN¥-84.97 Million | -0.060x | -402.15% |
| 2013-12-31 | CN¥1.29 Billion | CN¥-15.24 Million | -0.012x | +81.10% |
| 2012-12-31 | CN¥1.13 Billion | CN¥-70.62 Million | -0.063x | -463.52% |
| 2011-12-31 | CN¥987.45 Million | CN¥17.04 Million | 0.017x | -87.05% |
| 2010-12-31 | CN¥219.39 Million | CN¥29.25 Million | 0.133x | -12.34% |
| 2009-12-31 | CN¥159.19 Million | CN¥24.21 Million | 0.152x | +146.09% |
| 2008-12-31 | CN¥93.43 Million | CN¥-30.83 Million | -0.330x | -- |